XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Nov. 06, 2022
Nov. 06, 2022
Oct. 07, 2022
Jun. 30, 2022
Jun. 17, 2022
Nov. 08, 2021
Jun. 30, 2021
May 11, 2021
Apr. 09, 2021
Jan. 06, 2021
Aug. 12, 2020
Aug. 01, 2020
Jul. 15, 2020
Jul. 14, 2020
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Shares outstanding                                 3,894,792 2,666,667 1,475,000
Stock option vested exercisable term                                 15 months    
Stock options are exercisable price per share           $ 2.06                          
Stock based compensation                                 $ 1,546,040 $ 2,598,922  
Number of fully vested option exercisable 100,000 100,000       200,000                     2,819,792 2,004,167  
Share based compensation vesting rights, percentage                                 12.50%    
Total deferred compensation expense for outstanding value of unvested stock options                                 $ 882,000    
Intrinsic value of exercisable but unexercised in-the-money stock options                                 $ 750    
Fair market value, per share                                 $ 0.51    
Outstanding stock options to acquire shares of common stock not vested                                 1,075,000    
Director [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description                             the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $316,700 ($0.6334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024. During the year ended December 31, 2022, the Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $63,777 with respect to these stock options        
Stock option vested exercisable term       5 years                              
Stock options are exercisable price per share $ 0.5025 $ 0.5025         $ 0.74     $ 3.21           $ 0.74      
Fair value of stock options                   $ 571,312           $ 100,000      
Stock price per share $ 2.00 $ 2.00   $ 500,000     $ 0.6334     $ 2.8566         $ 500,000 $ 0.6334      
Stock based compensation                                 $ 63,777    
Number of fully vested option issued                   200,000                  
Number of fully vested option exercisable 200,000 200,000                                  
Five Non Officer Directors [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description             the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $3.03 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30, 2023. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $638,915 and $358,200, respectively, with respect to these stock options                        
Stock options are exercisable price per share             $ 3.03                 $ 3.03      
Fair value of stock options $ 43,264         $ 397,642                 $ 316,700 $ 1,421,095      
Stock price per share $ 0.4326 $ 0.4326       $ 1.9882 $ 2.84225                 $ 2.84225      
Stock based compensation                                 638,915 $ 358,200  
Number of fully vested option exercisable             100,000                 100,000      
Non Officer Directors [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of fully vested option exercisable             500,000                 500,000      
BasvanderBaan [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description         the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Baan was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($0.6341 per share), of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June 17, 2022 through June 30, 2024. During the year ended December 31, 2022, the Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $100,249 with respect to these stock options                            
Stock options are exercisable price per share         $ 0.74                            
Fair value of stock options         $ 158,525                            
Stock price per share         $ 0.6341                            
Stock based compensation                                 100,249    
Number of fully vested option exercisable         250,000                            
Stock options granted to purchase common stock, issued         $ 79,263                            
Four Officers [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock option vested exercisable term   5 years                                  
Fair value of stock options $ 262,560                                    
Stock price per share $ 0.3282 $ 0.3282                                  
Stock based compensation                                 75,520    
Number of fully vested option exercisable 800,000 800,000                                  
Share based compensation vesting rights, percentage 25.00%                                    
Share based compensation issuance, percentage 25.00%                                    
Stock options granted to purchase common stock, issued 800,000                                    
Dr Winson SzeChun Ho [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of fully vested option issued                   50,000                  
Dr Yun Yen [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of fully vested option issued                   50,000                  
Dr Stephen Forman [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of fully vested option issued                   50,000                  
Philip Palmedo [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of fully vested option issued                   50,000                  
Eric J. Forman [Member] | Employment Agreement [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options granted to purchase common stock, issued                         58,333            
Stock options description                         On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted stock options to purchase 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $100,213 and $100,213, respectively, with respect to these stock options            
Stock option vested exercisable term                         5 years            
Stock options are exercisable price per share                         $ 7.14            
Fair value of stock options                         $ 400,855            
Stock price per share                         $ 6.8718            
Stock options fully vested amount, fair value                     $ 100,214                
Stock based compensation                                 100,213 100,213  
Dr. James Miser [Member] | Employment Agreement [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options granted to purchase common stock, issued                       83,334              
Stock options description                       Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase 83,334 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $143,163 and $143,163, respectively, with respect to these stock options              
Stock options are exercisable price per share                       $ 7.14              
Fair value of stock options                       $ 572,650              
Stock price per share                       $ 6.8718              
Stock options fully vested amount, fair value                       $ 143,163              
Stock based compensation                                 143,163 143,163  
Robert N. Weingarten [Member] | Employment Agreement [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description                     On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $100,213 and $100,213, respectively, with respect to these stock options                
Stock options are exercisable price per share                     $ 7.14                
Fair value of stock options                     $ 400,855                
Stock price per share                     $ 6.8718                
Stock options fully vested amount, fair value                     $ 100,214                
Stock based compensation                                 100,213 100,213  
Dr Winson SzeChun Ho [Member] | Director [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description                 Winson Sze Chun Ho resigned from the Company’s Board of Directors to focus on clinical and pre-clinical cancer research in academic medicine. Concurrent with his resignation, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by Dr. Ho’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $3.20 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the portion of the stock options fully vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023, although vesting terminated on October 30, 2022, the date that Mr. Schwartzberg died. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $126,684 and $500,235, respectively, with respect to these stock options                    
Stock options are exercisable price per share                 $ 3.20                    
Fair value of stock options                 $ 753,611                    
Stock price per share                 $ 3.0144                    
Stock options fully vested amount, fair value                 $ 376,800                    
Stock based compensation                                 126,684 500,235  
Number of fully vested option exercisable                 250,000                    
Ms.Regina Brown [Member] | Director [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Stock options description               the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from May 11, 2021 through June 30, 2023. During the years ended December 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $154,042 and $427,944, respectively, with respect to these stock options                      
Stock options are exercisable price per share               $ 2.80                      
Fair value of stock options               $ 658,363                      
Stock price per share               $ 2.6335                      
Stock options fully vested amount, fair value               $ 329,188                      
Stock based compensation                                 $ 154,042 $ 427,944  
Number of fully vested option exercisable               250,000                      
2020 Stock Incentive Plan [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Common shares avaliable for issuable     1,800,000                                
Stock options granted to purchase common stock, issued     4,133,333                                
Shares outstanding                                 2,603,125    
Shares were available for issuance                                 1,530,208    
2020 Stock Incentive Plan [Member] | Maximum [Member]                                      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                      
Number of restricted stock issued                           2,333,333